PLoS ONE (Jan 2021)

Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy.

  • Luis E Echeverría,
  • Lyda Z Rojas,
  • Sergio Alejandro Gómez-Ochoa,
  • Oscar L Rueda-Ochoa,
  • Cristian David Sosa-Vesga,
  • Taulant Muka,
  • James L Januzzi,
  • Rachel Marcus,
  • Carlos A Morillo

DOI
https://doi.org/10.1371/journal.pone.0258622
Journal volume & issue
Vol. 16, no. 10
p. e0258622

Abstract

Read online

BackgroundChronic Chagas Cardiomyopathy (CCM) is a unique form of cardiomyopathy compared to other etiologies of heart failure. In CCM, risk prediction based on biomarkers has not been well-studied. We assessed the prognostic value of a biomarker panel to predict a composite outcome (CO), including the need for heart transplantation, use of left ventricular assist devices, and mortality.MethodsProspective cohort study of 100 adults with different stages of CCM. Serum concentrations of amino-terminal pro-B type natriuretic peptide (NT-proBNP), galectin-3 (Gal-3), neutrophil gelatinase-associated lipocalin (NGAL), high sensitivity troponin T (hs-cTnT), soluble (sST2), and cystatin-C (Cys-c) were measured. Survival analyses were performed using Cox proportional hazard models.ResultsDuring a median follow-up of 52 months, the mortality rate was 20%, while the CO was observed in 25% of the patients. Four biomarkers (NT-proBNP, hs-cTnT, sST2, and Cys-C) were associated with the CO; concentrations of NT-proBNP and hs-cTnT were associated with the highest AUC (85.1 and 85.8, respectively). Combining these two biomarkers above their selected cut-off values significantly increased risk for the CO (HR 3.18; 95%CI 1.31-7.79). No events were reported in the patients in whom the two biomarkers were under the cut-off values, and when both levels were above cut-off values, the CO was observed in 60.71%.ConclusionThe combination of NT-proBNP and hs-TnT above their selected cut-off values is associated with a 3-fold increase in the risk of the composite outcome among CCM patients. The use of cardiac biomarkers may improve prognostic evaluation of patients with CCM.